PRODUCTION OF BOTULINUM ANTI-TOXIN IMMUNOGLOBULIN Release Date: June 13, 2002 NOTICE: NOT-AI-02-030 National Institute of Allergy and Infectious Diseases (NIAID) (http://www.niaid.nih.gov) Receipt Date for Letter of Interest: July 12, 2002 The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting the development and licensure of botulinum anti-toxin immunoglobulin as a part of our Biodefense program. NIAID is interested in receiving letters from organizations that have the needed development and production capabilities. Interested organizations should submit a letter of interest that contains a detailed description of a potential development, production and marketing plan, as well as their R&D capabilities and interest. The letter of interest along with any supporting documentation shall not exceed 10 pages. Letters of interest will be kept confidential and will help in determining the need for an RFP to support further development, testing, and licensure of these products, and in assembling a potential source list for distribution if an RFP is issued. INQUIRIES Submit your response to the address listed below: Barbara A. Shadrick Senior Contracting Officer Contract Management Branch, DEA National Institute of Allergy and Infectious Diseases, NIH 6700-B Rockledge Drive, Room 2230, MSC 7612 Bethesda, MD 20892-7612 Phone: 301-496-7288 Fax: 301-480-5253 or 301-402-0972 E-Mail: bs92y@nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |